| 1 |
Tannins: Current knowledge of food sources, intake, bioavailability and biological effects
José C. E. Serrano, Riitta Puupponen‐Pimiä, Andreas Dauer et al. · Molecular Nutrition & Food Research
|
12 May 2009 |
810 |
| 2 |
Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development
John den Engelsman, Patrick Garidel, Ronald A. Smulders et al. · Pharmaceutical Research
Open access |
22 Oct 2010 |
354 |
| 3 |
Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood
ROBERT D. ROSENBERG, Ralf Gertler, Jan Friederichs et al. · Cytometry
Open access |
26 Nov 2002 |
301 |
| 4 |
The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity Antibodies
Christine Rothe, Stefanie Urlinger, Corinna Löhning et al. · Journal of Molecular Biology
|
14 Jan 2008 |
248 |
| 5 |
Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
Andreas Seidl, Otmar Hainzl, Marleen Richter et al. · Pharmaceutical Research
Open access |
17 Nov 2011 |
204 |
| 6 |
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
Christopher E.M. Griffiths, Diamant Thaçi, Sascha Gerdes et al. · British Journal of Dermatology
Open access |
20 Jan 2017 |
183 |
| 7 |
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Jan Marinus Visser, Isabel Feuerstein, Thomas Stangler et al. · BioDrugs
Open access |
6 May 2013 |
183 |
| 8 |
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
Andrew Blauvelt, J.‐P. Lacour, Joseph F. Fowler et al. · British Journal of Dermatology
|
19 Jun 2018 |
153 |
| 9 |
Cloning and expression of a cDNA encoding betanidin 5‐O‐glucosyltransferase, a betanidin‐ and flavonoid‐specific enzyme with high homology to inducible glucosyltransferases from the Solanaceae
Thomas Vogt, Rudi Grimm, Dieter Strack · The Plant Journal
Open access |
Sep 1999 |
146 |
| 10 |
Shedding of glycan‐modifying enzymes by signal peptide peptidase‐like 3 (SPPL3) regulates cellular N‐glycosylation
Matthias Voß, Ulrike Künzel, Fabian Higel et al. · The EMBO Journal
Open access |
29 Oct 2014 |
111 |
| 11 |
Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90
Edgar E. Boczek, Lasse G. Reefschläger, Marco Dehling et al. · Proceedings of the National Academy of Sciences
Open access |
8 Jun 2015 |
87 |
| 12 |
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
Martin Schiestl, Markus Zabransky, Fritz Sörgel · Drug Design Development and Therapy
Open access |
May 2017 |
84 |
| 13 |
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Wojciech J. Jurczak, Ilídia Moreira, Govind Babu Kanakasetty et al. · The Lancet Haematology
Open access |
14 Jul 2017 |
82 |
| 14 |
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon et al. · Annals of Oncology
Open access |
30 Jun 2015 |
81 |
| 15 |
Multiple switches between GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
Sascha Gerdes, Diamant Thaçi, Christopher E.M. Griffiths et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
28 Sep 2017 |
76 |
| 16 |
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support
Gary H. Lyman, Lillian C. Yau, Roumen Nakov et al. · Annals of Oncology
Open access |
5 Aug 2018 |
67 |
| 17 |
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Josef S Smolen, Stanley B. Cohen, Hans‐Peter Tony et al. · Annals of the Rheumatic Diseases
Open access |
22 Jun 2017 |
65 |
| 18 |
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
Bart Corsaro et al. · Bioanalysis
Open access |
3 Feb 2021 |
63 |
| 19 |
The Epidemiology of Acute Liver Failure
Nina Weiler, Andreas Schlotmann, Andreas Anton Schnitzbauer et al. · Deutsches Ärzteblatt international
Open access |
17 Jan 2020 |
63 |
| 20 |
Maintaining consistent quality and clinical performance of biopharmaceuticals
William C. Lamanna, Johann Holzmann, Hillel P. Cohen et al. · Expert Opinion on Biological Therapy
Open access |
29 Dec 2017 |
62 |
| 21 |
Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals
Fabian Higel, Uwe M. Demelbauer, Andreas Seidl et al. · Analytical and Bioanalytical Chemistry
Open access |
30 Jan 2013 |
62 |
| 22 |
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Stanley B. Cohen, Rieke Alten, Hideto Kameda et al. · Arthritis Research & Therapy
Open access |
27 Jul 2018 |
60 |
| 23 |
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance
Fabian Higel, Theresa Sandl, Chi-Ya Kao et al. · European Journal of Pharmaceutics and Biopharmaceutics
Open access |
21 Mar 2019 |
55 |
| 24 |
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
Fritz Sörgel, Arnd Schwebig, Johann Holzmann et al. · BioDrugs
Open access |
Apr 2015 |
54 |
| 25 |
Supportive care in patients with cancer during the COVID-19 pandemic
Matti Aapro, Gary H. Lyman, Carsten Bokemeyer et al. · ESMO Open
Open access |
5 Jan 2021 |
53 |
| 26 |
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis
Nurlan Dauletbaev, P.-A. Fischer, B Aulbach et al. · European journal of medical research
Open access |
12 Aug 2009 |
51 |
| 27 |
Fixed‐dose vs free‐dose combinations for the management of hypertension—An analysis of 81 958 patients
Peter Bramlage, Stefanie Schmidt, Helen M. Sims · Journal of Clinical Hypertension
Open access |
19 Feb 2018 |
50 |
| 28 |
Quantum Shuttle: traffic navigation with Quantum computing
Sheir Yarkoni, Florian Neukart, Eliane Moreno Gomez Tagle et al.
Conference paperOpen access |
13 Nov 2020 |
47 |
| 29 |
Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars
Kristof Vandekerckhove, Andreas Seidl, Hiten J. Gutka et al. · The AAPS Journal
Open access |
10 May 2018 |
47 |
| 30 |
Penetration of Cefaclor Into the Interstitial Space Fluid of Skeletal Muscle and Lung Tissue in Rats
Amparo de la Penña, Teresa Dalla Costa, James D. Talton et al. · Pharmaceutical Research
|
Sep 2001 |
47 |
| 31 |
Biowaiver Monographs for Immediate Release Solid Oral Dosage forms: Metoclopramide Hydrochloride
Andrea Stosik, Hans E. Junginger, Sabine Kopp et al. · Journal of Pharmaceutical Sciences
|
12 Feb 2008 |
46 |
| 32 |
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Antônio da Silva, Ulrich O. Kronthaler, Vera Koppenburg et al. · Leukemia & lymphoma/Leukemia and lymphoma
Open access |
11 Sep 2013 |
43 |
| 33 |
A mass spectrometry-based approach to host cell protein identification and its application in a comparability exercise
Veronika Reisinger, Hansjoerg Toll, Robert Ernst Mayer et al. · Analytical Biochemistry
|
17 Jun 2014 |
43 |
| 34 |
Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines
Tina Jarc, Maša Novak, Neli Hevir et al. · Journal of Pharmacy and Pharmacology
|
3 Jun 2019 |
42 |
| 35 |
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
Marco Matucci‐Cerinic, Yannick Allanore, Arthur Kavanaugh et al. · RMD Open
Open access |
Nov 2018 |
41 |
| 36 |
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
Kimberly Blackwell, Roman Donskih, C. Michael Jones et al. · The Oncologist
Open access |
18 Apr 2016 |
40 |
| 37 |
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs
Open access |
29 Oct 2020 |
38 |
| 38 |
Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach
Philipp Schick, Maximilian Sager, Franziska Wegner et al. · Molecular Pharmaceutics
|
8 Oct 2019 |
38 |
| 39 |
Randomized, Double-Blind Study Comparing Proposed Biosimilar La-Ep2006 with Reference Pegfilgrastim in Breast Cancer
Nadia Harbeck, Oleg Nikolaevich Lipatov, Мона Александровна Фролова et al. · Future Oncology
Open access |
29 Mar 2016 |
38 |
| 40 |
HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours
Karin Weigang-Köhler, Andrea Vetter, Ursula Thyroff‐Friesinger · Oncology Research and Treatment
|
2009 |
38 |
| 41 |
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
Oliver von Richter, Lena Lemke, Halimu N. Haliduola et al. · Expert Opinion on Biological Therapy
Open access |
30 Jan 2019 |
36 |
| 42 |
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
Fritz Sörgel, Ursula Thyroff‐Friesinger, Andrea Vetter et al. · BMC Clinical Pharmacology
Open access |
22 May 2009 |
36 |
| 43 |
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
Matti Aapro, Heinz Ludwig, Carsten Bokemeyer et al. · Annals of Oncology
Open access |
28 Oct 2016 |
35 |
| 44 |
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Janusz Jaworski, Marco Matucci‐Cerinic, Hendrik Schulze‐Koops et al. · Arthritis Research & Therapy
Open access |
28 May 2019 |
34 |
| 45 |
Biophysical Techniques for Characterizing the Higher Order Structure and Interactions of Monoclonal Antibodies
Yatin R. Gokarn, Sanjeev Agarwal, Kelly K. Arthur et al. · ACS symposium series
Conference paper |
2015 |
34 |
| 46 |
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective
Cathelijne P. A. M. Kloks, C Berger, Pierre Cortez et al. · Journal of Immunological Methods
|
17 Jan 2015 |
34 |
| 47 |
Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients
Edoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano · European Journal of Cancer
Review |
8 Dec 2017 |
33 |
| 48 |
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
Oliver von Richter, Andrej Skerjanec, Miguel Afonso Filipe et al. · British Journal of Clinical Pharmacology
Open access |
28 Oct 2016 |
33 |
| 49 |
Biosimilar granulocyte–colony‐stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Halvard B. Bonig, Petra S. A. Becker, Arnd Schwebig et al. · Transfusion
Open access |
26 Jun 2014 |
33 |
| 50 |
The structure-function relationship of disulfide bonds in etanercept
William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter et al. · Scientific Reports
Open access |
15 Jun 2017 |
32 |